This article is more than 5 years old. Information may no longer be current.
CMT reduced after phaco plus intravitreal injections in diabetic patients
Retina. 2011;31(4):755-758.
Click Here to Manage Email Alerts
The use of intravitreal bevacizumab and triamcinolone acetonide injections in conjunction with phacoemulsification in diabetic patients with clinically significant macular edema and cataract decreased central macular thickness and increased best corrected visual acuity, according to a study.
Twenty-two patients were examined before phacoemulsification surgery, and baseline BCVA, IOP, and central macular thickness were established. One eye of each patient underwent phacoemulsification with intravitreal injection of 1.25 mg bevacizumab and 2 mg triamcinolone acetonide.
Patients were examined at 1 day, 5 days, 4 weeks and 3 months postoperatively. BCVA values were statistically significantly higher 3 months postoperatively, and central macular thickness values were statistically significantly lower.
"Our results showed that the use of intravitreal 1.25 mg bevacizumab and 2 mg [triamcinolone acetonide] at the same session with phacoemulsification not only prevented the exacerbation of macular edema but also reduced the pre-existing edema," the study authors said.